Abbott Laboratories (ABT) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $104.68, +1.66% vs the prior close of $102.97.
- Volume 12.75M shares, 1.5x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ABT rises 1.7% to $104.68, a 1-month high, 5 up days in a row. Closed at $104.68, +1.66% vs the prior close of $102.97. Day range $104.09–$105.46, opened at $105.00.
ABT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ABT rises 1.7% to $104.68, a 1-month high, 5 up days in a row
- Closed at $104.68, +1.66% vs the prior close of $102.97. Day range $104.09–$105.46, opened at $105.00.
- Volume was 12.75M shares, 1.5x its 50-day average of 8.44M.
- Price is -1.2% vs its 50-day average ($105.93) and +1.7% vs its 200-day average ($102.91).
- 52-week range $81.97–$132.03; today's close sits at 45% of that range, 20.7% below the 52-week high.
- That makes 5 straight gains.
Oct 14, 2026 — ABT rises 0.4% to $102.97, 4 up days in a row
- Closed at $102.97, +0.35% vs the prior close of $102.61. Day range $101.69–$104.06, opened at $104.06.
- Volume was 7.29M shares, 0.9x its 50-day average of 8.45M.
- Price is -2.8% vs its 50-day average ($105.95) and -0.0% vs its 200-day average ($103.01).
- 52-week range $81.97–$133.34; today's close sits at 41% of that range, 22.8% below the 52-week high.
- That makes 4 straight gains.
Oct 13, 2026 — ABT rises 0.8% to $102.61, 3 up days in a row
- Closed at $102.61, +0.78% vs the prior close of $101.82. Day range $100.63–$103.44, opened at $102.59.
- Volume was 9.86M shares, 1.2x its 50-day average of 8.41M.
- Price is -3.2% vs its 50-day average ($106.00) and -0.5% vs its 200-day average ($103.12).
- 52-week range $81.97–$133.34; today's close sits at 40% of that range, 23.0% below the 52-week high.
- That makes 3 straight gains.
Oct 12, 2026 — ABT rises 2.2% to $101.82
- Closed at $101.82, +2.23% vs the prior close of $99.60. Day range $99.78–$102.06, opened at $100.00.
- Volume was 7.15M shares, 0.8x its 50-day average of 8.46M.
- Price is -4.0% vs its 50-day average ($106.09) and -1.4% vs its 200-day average ($103.23).
- 52-week range $81.97–$134.50; today's close sits at 38% of that range, 24.3% below the 52-week high.
Oct 9, 2026 — ABT rises 1.1% to $99.60
- Closed at $99.60, +1.13% vs the prior close of $98.49. Day range $98.20–$100.36, opened at $98.41.
- Volume was 6.96M shares, 0.8x its 50-day average of 8.48M.
- Price is -6.2% vs its 50-day average ($106.17) and -3.6% vs its 200-day average ($103.34).
- 52-week range $81.97–$135.13; today's close sits at 33% of that range, 26.3% below the 52-week high.
Oct 8, 2026 — ABT ends flat (-0.2%) to $98.49
- Closed at $98.49, -0.24% vs the prior close of $98.73. Day range $97.20–$99.20, opened at $98.56.
- Volume was 13.91M shares, 1.6x its 50-day average of 8.44M.
- Price is -7.3% vs its 50-day average ($106.29) and -4.8% vs its 200-day average ($103.47).
- 52-week range $81.97–$135.13; today's close sits at 31% of that range, 27.1% below the 52-week high.
Oct 7, 2026 — ABT rises 0.6% to $98.73
- Closed at $98.73, +0.58% vs the prior close of $98.16. Day range $97.62–$99.37, opened at $98.89.
- Volume was 9.39M shares, 1.1x its 50-day average of 8.51M.
- Price is -7.3% vs its 50-day average ($106.48) and -4.7% vs its 200-day average ($103.61).
- 52-week range $81.97–$135.13; today's close sits at 32% of that range, 26.9% below the 52-week high.
Oct 6, 2026 — ABT dips 1.9% to $98.16
- Closed at $98.16, -1.94% vs the prior close of $100.10. Day range $97.94–$100.95, opened at $100.56.
- Volume was 10.58M shares, 1.2x its 50-day average of 8.53M.
- Price is -8.0% vs its 50-day average ($106.65) and -5.4% vs its 200-day average ($103.74).
- 52-week range $81.97–$135.24; today's close sits at 30% of that range, 27.4% below the 52-week high.
Oct 5, 2026 — ABT rises 2.7% to $100.10
- Closed at $100.10, +2.67% vs the prior close of $97.50. Day range $97.39–$100.70, opened at $97.84.
- Volume was 11.99M shares, 1.4x its 50-day average of 8.50M.
- Price is -6.3% vs its 50-day average ($106.78) and -3.6% vs its 200-day average ($103.88).
- 52-week range $81.97–$135.37; today's close sits at 34% of that range, 26.1% below the 52-week high.
Oct 2, 2026 — ABT rises 0.8% to $97.50
- Closed at $97.50, +0.84% vs the prior close of $96.69. Day range $95.06–$97.59, opened at $97.25.
- Volume was 8.71M shares, 1.0x its 50-day average of 8.52M.
- Price is -8.7% vs its 50-day average ($106.84) and -6.3% vs its 200-day average ($104.01).
- 52-week range $81.97–$135.37; today's close sits at 29% of that range, 28.0% below the 52-week high.
ABT latest news & SEC filings
Every SEC filing by or about ABT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 25, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Conroy Kevin T had withheld for taxes 52,507 shares at $103.99 (≈$5.46M) on Sep 23, 2026; now holds 81,230
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 20, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Jul 28, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Key figures from this report aren't in the SEC's structured data yet (usually appears within a day or two).
Jul 16, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 18, 2026 · 11-K — Annual report for an employee stock plan
Annual report for an employee stock plan
Things to know before you trade ABT
- Last results release: Jul 16, 2026 (8-K Item 2.02). Previous ones: Apr 16, 2026, Jan 22, 2026, Oct 15, 2025. Based on that rhythm, the next report is likely around Oct 15, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.06% (largest 2.7%).
- Liquidity: about 9.83M shares (≈$1.03B) trade per day on average.
- 52-week position: $104.68 vs a range of $81.97–$132.03 (45% of the range).
- Dividends: last ex-dividend date Oct 15, 2026 ($0.63/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 6 open-market buys, 11 sales; latest: John A. Jr. Mccoy sold 27 shares on Sep 2, 2026.
- Latest filings: 8-K Aug 20, 2026; 10-Q Jul 28, 2026; 8-K Jul 16, 2026.
- Share count: 1.74B shares outstanding (Mar 31, 2026), +0.1% vs a year earlier.
- Listing: NYSE · industry: Pharmaceutical Preparations.
ABT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 105.00 | 105.46 | 104.09 | 104.68 | 12.75M |
| Oct 14, 2026 | 104.06 | 104.06 | 101.69 | 102.97 | 7.29M |
| Oct 13, 2026 | 102.59 | 103.44 | 100.63 | 102.61 | 9.86M |
| Oct 12, 2026 | 100.00 | 102.06 | 99.78 | 101.82 | 7.15M |
| Oct 9, 2026 | 98.41 | 100.36 | 98.20 | 99.60 | 6.96M |
| Oct 8, 2026 | 98.56 | 99.20 | 97.20 | 98.49 | 13.91M |
| Oct 7, 2026 | 98.89 | 99.37 | 97.62 | 98.73 | 9.39M |
| Oct 6, 2026 | 100.56 | 100.95 | 97.94 | 98.16 | 10.58M |
| Oct 5, 2026 | 97.84 | 100.70 | 97.39 | 100.10 | 11.99M |
| Oct 2, 2026 | 97.25 | 97.59 | 95.06 | 97.50 | 8.71M |
| Oct 1, 2026 | 99.10 | 99.45 | 96.54 | 96.69 | 8.86M |
| Sep 30, 2026 | 100.57 | 100.63 | 98.72 | 98.83 | 7.57M |
| Sep 29, 2026 | 100.26 | 101.07 | 99.48 | 100.95 | 8.05M |
| Sep 28, 2026 | 101.08 | 101.76 | 100.26 | 100.98 | 6.80M |
| Sep 25, 2026 | 100.81 | 101.82 | 100.09 | 101.29 | 7.78M |
| Sep 24, 2026 | 103.77 | 104.22 | 101.02 | 101.07 | 6.22M |
| Sep 23, 2026 | 104.22 | 104.31 | 102.66 | 103.49 | 12.18M |
| Sep 22, 2026 | 104.01 | 104.54 | 102.90 | 103.69 | 8.38M |
| Sep 21, 2026 | 102.27 | 103.20 | 101.84 | 102.98 | 5.02M |
| Sep 18, 2026 | 101.83 | 103.19 | 101.50 | 102.61 | 27.08M |
About Abbott Laboratories
Abbott Laboratories (ABT) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in ABBOTT PARK, IL. State of incorporation: IL. Fiscal year ends December 31. SEC CIK 1800.
ABT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Nita Ahuja | Director | Jul 1, 2026 |
| Robert J Alpern | Director | Apr 2, 2026 |
| Claire Babineaux-Fontenot | Director | Apr 28, 2026 |
| Sally E. Blount | Director | Apr 28, 2026 |
| Kevin T Conroy | Director | Sep 25, 2026 |
| Robert B Ford | CHAIRMAN AND CEO | Aug 27, 2026 |
| Patricia Paola Gonzalez | Director | Jul 1, 2026 |
| Michelle Kumbier | Director | Apr 28, 2026 |
| Darren W Mcdew | Director | Apr 28, 2026 |
| Nancy Mckinstry | Director | Apr 28, 2026 |
| Michael O'Grady | Director | Apr 28, 2026 |
| Michael F Roman | Director | Jul 1, 2026 |
| Daniel J Starks | Director | Apr 28, 2026 |
| John G Stratton | Director | Jul 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Philip P Boudreau | EVP AND CFO | Sep 3, 2026 |
| Elizabeth C. Cushman | EVP, GC AND SECRETARY | Jun 29, 2026 |
| Lisa D Earnhardt | EVP AND GROUP PRESIDENT | Mar 3, 2026 |
| Robert B Ford | CHAIRMAN AND CEO | Aug 27, 2026 |
| John A. Jr. Mccoy | VICE PRESIDENT AND CONTROLLER | Sep 3, 2026 |
| Mary K Moreland | EXECUTIVE VICE PRESIDENT | Apr 29, 2026 |
| Louis H. Morrone | EXECUTIVE VICE PRESIDENT | Aug 13, 2026 |
| Jacob A Orville | Senior Vice President | Mar 25, 2026 |
| Daniel Gesua Sive Salvadori | EVP AND GROUP PRESIDENT | Mar 3, 2026 |
| Christopher J Scoggins | EXECUTIVE VICE PRESIDENT | Mar 3, 2026 |
| Eric Shroff | Senior Vice President | Mar 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | John A. Jr. Mccoy | Sale | 27 | $109.54 |
| Aug 25, 2026 | Robert B Ford | Sale | 218,535 | $115.57 |
| Aug 25, 2026 | Robert B Ford | Sale | 180,297 | $116.19 |
| Aug 11, 2026 | Louis H. Morrone | Sale | 5,850 | $109.83 |
| May 7, 2026 | John G Stratton | Buy | 2,000 | $86.82 |
| Apr 27, 2026 | Daniel J Starks | Buy | 10,000 | $92.65 |
| Apr 23, 2026 | Philip P Boudreau | Buy | 2,200 | $91.50 |
| Mar 2, 2026 | Louis H. Morrone | Sale | 1,144 | $115.58 |
| Mar 2, 2026 | Mary K Moreland | Sale | 613 | $115.58 |
| Mar 2, 2026 | John A. Jr. Mccoy | Sale | 585 | $115.58 |
| Mar 2, 2026 | Elizabeth C. Cushman | Sale | 263 | $115.58 |
| Mar 2, 2026 | Daniel Gesua Sive Salvadori | Sale | 885 | $115.58 |
| Mar 2, 2026 | Eric Shroff | Sale | 709 | $115.58 |
| Feb 4, 2026 | Daniel J Starks | Buy | 5,033 | $108.33 |
| Feb 4, 2026 | Daniel J Starks | Buy | 4,967 | $109.14 |
ABT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $44.33B | $6.52B | 3.72 | $9.57B |
| Dec 31, 2024 | $41.95B | $13.40B | 7.64 | $8.56B |
| Dec 31, 2023 | $40.11B | $5.72B | 3.26 | $7.26B |
| Dec 31, 2022 | $43.65B | $6.93B | 3.91 | $9.58B |
| Dec 31, 2021 | $43.08B | $7.07B | 3.94 | $10.53B |
Latest balance sheet: total assets $110.43B, total liabilities $—, cash $6.80B (as of Mar 31, 2026).
ABT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 16, 2026 | 8-K Item 2.02 (results) | $98.83 |
| Apr 16, 2026 | 8-K Item 2.02 (results) | $95.47 |
| Jan 22, 2026 | 8-K Item 2.02 (results) | $108.61 |
| Oct 15, 2025 | 8-K Item 2.02 (results) | $129.45 |
| Jul 17, 2025 | 8-K Item 2.02 (results) | $120.51 |
| Apr 16, 2025 | 8-K Item 2.02 (results) | $129.70 |
| Jan 22, 2025 | 8-K Item 2.02 (results) | $117.78 |
| Oct 16, 2024 | 8-K Item 2.02 (results) | $117.82 |
| Jul 18, 2024 | 8-K Item 2.02 (results) | — |
| Apr 17, 2024 | 8-K Item 2.02 (results) | — |
| Jan 24, 2024 | 8-K Item 2.02 (results) | — |
| Oct 18, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ABT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.